Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2014-03-13 Director's Dealing
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Director's Dealing 2014
Director's Dealing Classification · 99% confidence The document explicitly states it is a 'Report Pursuant to Section 28a of the Danish Securities Trading Act' and details transactions (sales) involving shares by managerial employees and board members (Anders Gersel Pedersen, Burton G. Malkiel, Nedjad Losic). This content directly corresponds to the definition of reporting personal share transactions by company directors and executives, which is classified as Director's Dealing (DIRS). The document is a formal announcement of these insider trades.
2014-03-13 English
Director's Dealing 2014
Director's Dealing Classification · 99% confidence The document is titled 'Selskabsmeddelelse' (Company Announcement) and explicitly states that it is reporting transactions made by leading employees and their close associates regarding company shares, referencing the Danish Securities Trading Act (§ 28a). The content details specific purchases (utilization of warrants) by the CEO and Board Members, including transaction dates, number of shares, and value. This content directly corresponds to the definition of insider trading reports or director's dealings. Among the provided codes, 'DIRS' (Director's Dealing) is the most appropriate classification for reports detailing personal share transactions by company directors and executives.
2014-03-12 Danish
Director's Dealing 2014
Director's Dealing Classification · 100% confidence The document explicitly details transactions (Purchases via warrant exercise) involving shares of Genmab A/S by its managerial employees (President & CEO, Board Members). This type of disclosure, reporting personal share transactions by directors and executives, directly corresponds to the definition of Director's Dealing. The relevant code is DIRS.
2014-03-12 English
Share Issue/Capital Change 2014
Share Issue/Capital Change Classification · 99% confidence The document is titled "Kapitalforhøjelse i Genmab som følge af udnyttelse af medarbejderwarrants" (Capital increase in Genmab due to exercise of employee warrants) and is explicitly labeled as a "Selskabsmeddelelse" (Company Announcement). It details a specific corporate action: an increase in share capital due to the exercise of warrants, including the number of new shares, the subscription prices, and the impact on key executives' holdings. This type of announcement, concerning changes in capital structure or financing activities, aligns best with the 'Capital/Financing Update' category (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it concerns a specific capital event.
2014-03-12 English
Share Issue/Capital Change 2014
Share Issue/Capital Change Classification · 99% confidence The document is titled "Company Announcement" and details a specific corporate action: an increase in share capital resulting from the exercise of employee warrants. It specifies the number of shares, the subscription prices, the total proceeds, and notes that this involves transactions by executives and board members. This directly relates to changes in the company's capital structure and share count. The most appropriate classification among the provided options is 'Share Issue/Capital Change' (SHA), as it describes the issuance of new shares due to warrant exercise, which alters the capital structure. It is not a general regulatory filing (RNS) because it fits a specific category, nor is it a dividend notice (DIV) or director's dealing (DIRS), although insider transactions are mentioned as part of the context of the warrant exercise.
2014-03-12 English
Legal Proceedings Report 2014
Legal Proceedings Report Classification · 99% confidence The document is titled "Company Announcement" and details a clinical trial update regarding a partnership between Genmab and Janssen concerning the drug daratumumab. It discusses future plans (Phase III study initiation, patient recruitment) and provides general company and product information. This type of communication, which is not a formal financial report (like 10-K or IR), a specific regulatory filing (like DIRS or DIV), or a transcript, fits best under a general regulatory/company update category. Since it is a formal announcement of business progress rather than a specific financial result (ER) or a presentation (IP), and it doesn't fit the other specific categories, the most appropriate classification is Regulatory Filings (RNS) as a general corporate disclosure, or potentially Investor Presentation (IP) if it were structured as a slide deck, but its format suggests a press release/announcement. Given the options, RNS serves as the best catch-all for significant, non-standardized corporate news releases. The length (4843 chars) is substantial enough that it is not just a brief notification of a report being available (RPA).
2014-03-05 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.